Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD )

2.300 -1.420 (-38.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stocks Mixed, Headed For Monthly Wins
In what appears to be a theme this week, stocks are hesitant midday as investors unpack this morning's jobs and inflation data. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?
Ironwood Pharmaceuticals' SBS-IF treatment Apraglutide's Phase 3 trial met primary endpoints, reducing PS dependency by 25.5% vs. placebo, but misses on two key secondary endpoints. 
Via Benzinga
Nasdaq Gains 100 Points Following PCE Data
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the... 
Via Benzinga
Topics Stocks
Exposures US Equities
PSNY Stock Alert: Polestar Makes Moves With Its Joint Venture
Polestar stock is rising higher on Thursday as holders of PSNY shares react to an update for the company's Chinese joint venture. 
Via InvestorPlace
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
A Preview Of Ironwood Pharmaceuticals's Earnings
Via Benzinga
Chart Of The Day: Ironwood Pharma - Gastrointestinal Products
Via Talk Markets
Ironwood Pharmaceuticals Ran Up 32% Over Two Months — And Just Lost It All
The company still plans to ask for approval of its short bowel syndrome treatment. 
Via Investor's Business Daily
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&P 500, and small caps. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?
Ironwood Pharmaceuticals stock is falling on Thursday with investors in IRWD unimpressed by its latest Phase III clinical trial results. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning! 
Via InvestorPlace
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Top 4 Health Care Stocks You May Want To Dump In February
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
Via Newsfile
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.